Global News

Heat Biologics, OncoSec Medical collaborate on immunotherapy platforms

Thursday, February 19, 2015 02:38 PM

Heat Biologics, a clinical stage biopharmaceutical company developing cancer immunotherapies based in Durham, N.C., and OncoSec Medical, a San Diego, Calif.-based company developing DNA-based intratumoral cancer immunotherapies, have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company.

More... »


Ferring Pharmaceuticals acquires BioSET orthobiologic product candidates

Thursday, February 19, 2015 02:37 PM

Ferring Pharmaceuticals, based in Saint Prex, Switzerland, has acquired the assets of Maryland-based BioSurface Engineering Technologies (BioSET), including two phase III ready orthobiologic product candidates designed to improve bone repair. The initial indications for Amplex and Prefix to be investigated are fusion in foot/ankle and lumbar spine surgical procedures, respectively. Both products are based on a unique biomimetic peptide designed to enhance the body’s own natural mechanisms of bone repair.

More... »


Pharming appoints Dr. Perry Calias chief scientific officer

Thursday, February 19, 2015 02:17 PM

Pharming Group has appointed Dr. Perry Calias chief scientific officer. Calias will have overall responsibility for the company's new enzyme replacement therapy (ERT) programs, achieving the scientific milestones set in the business plan, enhancing the IP portfolio, overseeing new product development and contributing to the overall strategic direction of the company.

More... »

DrugDev appoints chief business officer Nick Watling

Thursday, February 19, 2015 01:26 PM

DrugDev has announced the appointment of Nick Watling to the new position of chief business officer as the company continues its rapid growth to meet increasing customer demand. Watling will lead strategic initiatives to further enhance DrugDev’s operational performance and enable it to continue providing support to customers. He also will oversee the human resources, quality and administration functions.

More... »

Altasciences companies receive CRO Leadership Awards

Thursday, February 19, 2015 01:08 PM

Altasciences has announced that its companies, Algorithme Pharma (Montreal, Canada) and Vince & Associates Clinical Research (Kansas), are both 2015 CRO Leadership Award recipients.

More... »

Theorem Clinical Research, Biomedical Systems partner

Wednesday, February 18, 2015 11:58 AM

Theorem Clinical Research, a global CRO based in King of Prussia, Pa., and Biomedical Systems, a provider of comprehensive centralized diagnostic services, have formed a strategic partnership to expand a suite of services available to clients worldwide.

More... »

Actavis to divest Pharmatech to TPG

Wednesday, February 18, 2015 11:57 AM

Actavis, headquartered in Dublin, and TPG, a global private investment firm, have entered into definitive agreements under which Actavis will divest to TPG the business currently known as Aptalis Pharmaceutical Technologies (Pharmatech)—a pharmaceutical outsourcing and R&D business operating in the U.S., Canada and Europe (where the transaction is, in certain jurisdictions, still subject to local regulations, discussions and clearances). No other Aptalis businesses or products are included in the transaction. Financial terms have not been disclosed. 

More... »

CRF Health, Vodafone partner

Wednesday, February 18, 2015 11:56 AM

CRF Health, a global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry based in Plymouth Meeting, Pa., has announced a new partnership with Vodafone, a British multinational telecommunications company. CRF Health will use Vodafone’s global Machine-to-Machine (M2M) platform to offer an enhanced service to clinical trial operators and their patients.

More... »

Sanofi, Lead Pharma partner to develop treatments for autoimmune diseases

Wednesday, February 18, 2015 11:55 AM

Sanofi has entered into a research collaboration and license agreement with Dutch biotech Lead Pharma to discover, develop and commercialize small-molecule therapies directed against the nuclear hormone receptors called ROR gamma t to treat a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease, which are among the most common.

More... »

Certara to launch version 8.0 of D360 big data platform

Wednesday, February 18, 2015 11:54 AM

Certara, a global biosimulation technology-enabled drug development and drug safety consulting company, will be launching version 8.0 of its D360 R&D big data platform for the biopharmaceutical industry.

More... »

`

CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs